Ogivri Injection 440 mg/20 ml contains Trastuzumab, a monoclonal antibody used in the treatment of certain HER2-positive cancers. It is a targeted biological therapy designed to specifically act on cancer cells that overexpress the human epidermal growth factor receptor 2 (HER2). By targeting this receptor, Ogivri Injection helps slow or stop the growth of cancer cells while minimizing damage to normal healthy tissues. It is widely used in oncology practice and plays a crucial role in improving survival and disease control in eligible patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each 20 ml vial contains:

• Trastuzumab 440 mg

Therapeutic Class

Antineoplastic agent
Monoclonal antibody (HER2 inhibitor)

Mechanism of Action

Trastuzumab selectively binds to the extracellular domain of the HER2 receptor, which is overexpressed in certain types of cancer cells, particularly breast and gastric cancers. This binding inhibits HER2-mediated signaling pathways responsible for cell growth and proliferation. In addition, trastuzumab activates immune-mediated mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), leading to targeted destruction of HER2-positive cancer cells. This dual mechanism helps reduce tumor growth and progression.

Indications

Ogivri Injection is indicated for the treatment of patients with HER2-positive cancers, including:

• HER2-positive early breast cancer

• HER2-positive metastatic breast cancer

• HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma

HER2 status should be confirmed using validated diagnostic tests before initiating therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

Ogivri Injection is administered by intravenous infusion under the supervision of a qualified healthcare professional experienced in cancer chemotherapy. The dosage and treatment schedule depend on the type of cancer, patient body weight, treatment regimen, and clinical response. It may be used alone or in combination with other anticancer therapies as determined by the treating oncologist.

Benefits and Features

• Targeted therapy for HER2-positive cancers

• Helps slow disease progression and improve survival outcomes

• Selective action reduces damage to normal cells

• Can be used in early-stage and advanced cancers

• Well-established efficacy when used according to clinical guidelines

Precautions and Warnings

• Cardiac function should be evaluated before and during treatment, as trastuzumab may cause cardiotoxicity

• Use with caution in patients with pre-existing heart disease

• Infusion-related reactions such as fever, chills, or shortness of breath may occur

• Not recommended during pregnancy due to potential fetal harm

• Treatment should be discontinued if severe adverse reactions develop

Possible Side Effects

Common side effects may include fever, chills, headache, nausea, vomiting, diarrhea, fatigue, and infusion-related reactions. Serious but less common side effects include heart failure, lung toxicity, and severe allergic reactions. Patients should be closely monitored throughout therapy.

Storage

Store Ogivri Injection in a refrigerator at 2°C–8°C. Do not freeze. Protect from light and keep out of reach of children. Reconstituted solution should be used according to manufacturer and hospital guidelines.